Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Celldex Therapeutics, Inc. Director's Dealing 2008

Jan 4, 2008

31801_dirs_2008-01-04_deed7e86-4297-40ba-bebd-124ea807bb70.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2008-01-02

Reporting Person: FREEMAN PAULA R (Sr.Dir.Human Resources)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2008-01-02 Common Stock L 500 $.425 Acquired 2955 Direct